GeneScience Pharmaceuticals

Rani Therapeutics, LLC is a clinical-stage biotherapeutics company that focuses on the development of oral delivery technologies for large drug molecules, such as peptides, proteins, and antibodies. The company has created the RaniPill capsule, a proprietary and patented platform designed to administer biologics orally, offering a convenient alternative to traditional subcutaneous or intravenous injections. This capsule is engineered to deliver precise therapeutic doses upon reaching the small intestine. Rani Therapeutics is advancing various treatments, including TNFa inhibitors for inflammatory disorders, parathyroid hormone for osteoporosis, and human growth hormone for growth deficiencies. Additionally, their portfolio includes therapies for multiple sclerosis, type II diabetes, and various inflammatory diseases. Founded in 2012 and based in San Jose, California, Rani Therapeutics has conducted several preclinical and clinical studies to assess the safety and effectiveness of its technologies, building a robust intellectual property portfolio in the process.